Alvotech ALVO
4.54 USD +0.06 (+1.34%)
At closeNov 3, 2026, 4:00 PM EST
4.54 0.00 0.00%
After hours · Nov 3, 4:00 PM ET
4.48 Day range 4.65
2.94 52-week range 6.53
- YTD
- -11.50%
- 1 year
- -9.74%
News
seekingalpha.com Alvotech: The Market Is Still Pricing The Broken Factory Alvotech is transitioning from supply remediation to throughput, with FDA-cleared facilities and multiple key biosimilar filings advancing toward decisions this quarter. ALVO's guidance implies a…
globenewswire.com Alvotech to Present at Upcoming Investor Conferences in November REYKJAVIK, ICELAND (November 2, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients…
globenewswire.com Alvotech to Report Financial Results for the Nine-Month Period to September 30, 2026 REYKJAVIK, ICELAND (October 28, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for…
zacks.com New Strong Sell Stocks for October 21st ALVO, CSIQ and AESI have been added to the Zacks Rank #5 (Strong Sell) List on October 21, 2026.
globenewswire.com Alvotech receives FDA approval for new SIMLANDI® manufacturing process that more than doubles output per batch Enhanced process increases manufacturing productivity and frees up capacity to support growing demand across Alvotech's biosimilars portfolio
globenewswire.com Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg AVT29 submitted to the European Medicines Agency as a line extension to the existing marketing authorization for Mynzepli® (aflibercept 2 mg)
defenseworld.net Alvotech (NASDAQ:ALVO) Stock Has Consensus Target Price of $8.50 According to Brokerages Shares of Alvotech (NASDAQ: ALVO - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the eight brokerages that are covering the firm, Marketbeat reports. One equities…
benzinga.com Alvotech And LOTTE Biologics Announce Long-Term Strategic Manufacturing Partnership For Biosimilar Products Collaboration covers multiple biosimilar products to be manufactured at LOTTE Biologics’ Syracuse facility in New YorkStrategic long-term partnership to increase Alvotech’s global manufacturing…
globenewswire.com Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply Collaboration covers multiple biosimilar products to be manufactured at LOTTE Biologics' Syracuse facility in New York Strategic long-term partnership to increase Alvotech's global manufacturing…
benzinga.com Alvotech Gets FDA Nod For Added US Manufacturing Capacity For Humira Biosimilar SIMLANDI, Doubling Drug Substance Capacity At Reykjavik Site Approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of Alvotech’s two Reykjavik drug substance suitesFurther confirms resolution of FDA inspection-related…
globenewswire.com FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech's biosimilar to Humira® Approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of Alvotech's two Reykjavik drug substance suites
defenseworld.net Alvotech (NASDAQ:ALVO) Receives $8.50 Average Target Price from Brokerages Alvotech (NASDAQ: ALVO - Get Free Report) has been given an average rating of "Moderate Buy" by the eight analysts that are currently covering the firm, Marketbeat reports. One analyst has rated the…
benzinga.com LuxExperience, Alvotech, Twist Bioscience And Other Big Stocks Moving Higher On Wednesday U.S. stocks mixed as Nasdaq rises; LuxExperience jumps 13.5% on strong sales, while Einride, Forgent, Cipher and others post gains.
benzinga.com Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday Analysts raised targets for RAPP, ALLR, UNP and ALVO; cut targets for NU, CLLS and JBHT, with several rating upgrades and downgrades.
benzinga.com This Union Pacific Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday Analysts upgraded Similarweb, Rocket Pharmaceuticals, Radiant Logistics and Ulta Beauty; Paychex rose to Peer Perform, with targets raised.
benzinga.com Barclays Upgrades Alvotech to Overweight, Raises Price Target to $8 Barclays analyst Glen Santangelo upgrades Alvotech (NASDAQ:ALVO) from Underweight to Overweight and raises the price target from $4 to $8.
seekingalpha.com Alvotech (ALVO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Alvotech (ALVO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
defenseworld.net Financial Survey: Alvotech (NASDAQ:ALVO) & Alumis (NASDAQ:ALMS) Alumis (NASDAQ: ALMS - Get Free Report) and Alvotech (NASDAQ: ALVO - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies…
globenewswire.com Alvotech announces FDA acceptance for review of Biologics License Application for AVT80, expanding proposed biosimilar program for Entyvio® to subcutaneous presentations REYKJAVIK, Iceland, August 31, 2026 - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide,…
globenewswire.com Alvotech to present at upcoming investor conferences in September REYKJAVIK, ICELAND (August 27, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Innovative Eyewear (NASDAQ:LUCY) stock rose 63.6% to $1.12 during Monday's regular session. The market value of their outstanding shares is at $5.8 million. Picard Medical (AMEX:PMI) shares…
benzinga.com Crude Oil Down 3%; XPeng Shares Fall After Q2 Results US stocks traded mixed with the Dow Jones index gaining over 150 points. Consumer staples shares jumped while information technology stocks fell. XPeng Inc shares fell 7% due to wider than expected…
benzinga.com Napco Security Technologies Posts Upbeat Q4 Results, Joins Alvotech, Rum Group And Other Big Stocks Moving Higher On Monday U.S. stocks were mixed, with the Dow Jones index gaining around 150 points on Monday.
benzinga.com Napco Security Technologies Posts Upbeat Q4 Results, Joins Alvotech, Rum Group And Other Big Stocks Moving Higher On Monday The text discusses recent gains in the stock market, particularly for companies like Napco Security Technologies and SuperX AI Technology. US stocks were mixed, with the Dow Jones index gaining 150…
benzinga.com B of A Securities Initiates Coverage On Alvotech with Buy Rating, Announces Price Target of $7 B of A Securities analyst Jason Gerberry initiates coverage on Alvotech (NASDAQ:ALVO) with a Buy rating and announces Price Target of $7.
globenewswire.com Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets REYKJAVIK, Iceland, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for…
seekingalpha.com Alvotech: Reiterate Hold On AVT05/AVT06 BLA Resubmissions And Upcoming Catalysts Alvotech maintains at a Hold rating due to missed H1 2026 earnings and ongoing regulatory challenges, despite pipeline progress. Recent FDA CRLs for AVT05 and AVT06 were due to manufacturing issues,…
seekingalpha.com Alvotech (ALVO) Q2 2026 Earnings Call Transcript Alvotech (ALVO) Q2 2026 Earnings Call Transcript
marketbeat.com Alvotech Q2 Earnings Call Highlights Alvotech NASDAQ: ALVO said its first-half 2026 results reflected a temporary manufacturing slowdown tied to facility and quality-system improvements at its Reykjavik site, while management reaffirmed…
benzinga.com Alvotech Q2 2026 Earnings Call Transcript Alvotech (NASDAQ:ALVO) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by…
zacks.com Alvotech (ALVO) Reports Q2 Loss, Beats Revenue Estimates Alvotech (ALVO) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to earnings of $0.14 per share a year ago.
benzinga.com Alvotech Q2 EPS $(0.17) Misses $(0.04) Estimate, Sales $106.000M Miss $111.010M Estimate Alvotech (NASDAQ:ALVO) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.04) by 325 percent. This is a 221.43 percent decrease over earnings of $0.14…- benzinga.com Alvotech Affirms FY2026 Sales Guidance of $650.000M-$700.000M vs $644.838M Est Alvotech (NASDAQ:ALVO) affirms FY2026 sales outlook from $650.000 million-$700.000 million to $650.000 million-$700.000 million vs $644.838 million estimate.
benzinga.com AstraZeneca, GameStop, Snap And Other Big Stocks Moving Lower In Monday’s Pre-Market Session U.S. stock futures higher, AstraZeneca dips on merger talks, Apple down 7.4%, other stocks moving lower in pre-market trading.
benzinga.com Why Atkore Shares Are Trading Higher By 26%; Here Are 20 Stocks Moving Premarket Atkore Inc (ATKR) shares rise on strong Q3 results and acquisition by Prysmian for $95.00 per share. Other gainers include UPC, YYAI, RITR, FCUV, SGLY, FNGR, ALAR, FERG, and BMY while FMFC, PWCM,…
benzinga.com Alvotech Says FDA Closes Inspection Of Manufacturing Facility In Reykjavik, Iceland; FDA Confirms Inspection Classification Of Manufacturing Site Is Voluntary Action Indicated Alvotech (NASDAQ:ALVO, ALVO-SDB))) (the "Company"), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that…
benzinga.com Alvotech Strengthens Liquidity With $75M Term Loan, Building On Recent $165M Equity Raise For Total $240M In New Capital — $75 million additional term loan facility maturing December 31, 2027, led by GoldenTree Asset Management— Follows recent $165m equity raise strengthening cash position— Including equity financing…
benzinga.com Dave and Buster's Reports Downbeat Q1 Earnings, Joins Alvotech And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session US stock futures up 0.1%, Dave and Buster's (PLAY) down 13.4% pre-market due to lower earnings; other stocks declining in pre-market trading
benzinga.com Why High Tide Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket HITI rose sharply in pre-market trading on strong Q2 results and continued to rise after market open. Other gainers include SLBT, TDIC, IMCC, IVDA, NXTS, CRVO, PAVS, ALBT, and PURR. Losers include…- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com Alvotech Commences ~$125M Offering Of Ordinary Shares Alvotech (NASDAQ:ALVO, ALVO-SDB))) ("Alvotech" or the "Company"), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com Earnings Scheduled For May 6, 2026 - benzinga.com Alvotech Q1 Sales $105.900M Miss $140.847M Estimate Alvotech (NASDAQ:ALVO) reported quarterly sales of $105.900 million which missed the analyst consensus estimate of $140.847 million by 24.81 percent. This is a 20.26 percent decrease over sales of…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com Mach Natural Resources, Mesoblast And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session U.S. stock futures down, Nasdaq 100 falls over 100 points. Mach Natural Resources LP (MNR) shares dip 7.6% in pre-market trading.
benzinga.com Why nCino Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket Shares of nCino Inc (NASDAQ: NCNO) jumped 18% in pre-market trading after reporting strong Q4 results and issuing positive guidance for Q1 and FY27.- benzinga.com UBS Maintains Buy on Alvotech, Lowers Price Target to $6 UBS analyst Ashwani Verma maintains Alvotech (NASDAQ:ALVO) with a Buy and lowers the price target from $10 to $6.
- benzinga.com Barclays Maintains Underweight on Alvotech, Lowers Price Target to $4 Barclays analyst Glen Santangelo maintains Alvotech (NASDAQ:ALVO) with a Underweight and lowers the price target from $5 to $4.
benzinga.com Alvotech Q4 Sales $173.200M Beat $159.927M Estimate Alvotech (NASDAQ:ALVO) reported quarterly sales of $173.200 million which beat the analyst consensus estimate of $159.927 million by 8.30 percent. This is a 12.95 percent increase over sales of…